A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery

P Pautier,A Floquet,C Chevreau,N Penel,C Guillemet,C Delcambre,D Cupissol, F Selle, N Isambert,S Piperno-Neumann,E Saada-Bouzid,F Bertucci,E Bompas,J Alexandre,O Collard,V Lebrun-Ly, P Soulier,M Toulmonde,A Le Cesne,B Lacas,F Duffaud

ESMO Open（2021）

引用 17|浏览6

暂无评分

摘要

•Long-term results on PFS and OS of doxorubicin and trabectedin in first-line treatment for advanced leiomyosarcoma.•The update confirms the impressive efficiency of the doxo+trab in terms of PFS and OS.•Results of a randomized phase-III study comparing dox+trab combination versus doxo alone in first-line therapy in metastatic LMS are pending.

查看译文

关键词

leiomyosarcoma,first-line chemotherapy,doxorubicin plus trabectedin

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要